| |
|
|
|
Xtalks, Online
2025-04-17
As antibody-drug conjugates (ADCs) advance in precision oncology, diagnostics play a vital role in identifying eligible patients, validating biomarkers and supporting regulatory approval.
Companion diagnostics (CDx) enable targeted therapies by confirming the presence of specific biomarkers, helping to match patients with the most appropriate treatments. A well-integrated diagnostic strategy ensures that ADC development is optimized for clinical success and regulatory readiness.
In this webinar, Dr. Yuri Fesko will explore the expanding role of precision diagnostics in ADC development and how strategic diagnostic partnerships can help streamline biomarker validation, patient selection and regulatory alignment.
Register for this webinar today to explore the critical role of companion diagnostics in antibody-drug conjugate development.
Keywords: Antibody, Oncology, Biomarkers, Regulatory, Companion Diagnostics, Regulatory Approval, CDx, Diagnostics, Antibody-Drug Conjugate, Antibody Drug, Precision Oncology
|
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
|
Invited Speakers:
|
|
Dr. Yuri Fesko, MD, Chief Medical Officer, Quest Diagnostics
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2025-04-17
|
|
|
|
|
|
|
|
Registration:
|
|
Free Registration
|
|
|
E-mail:
|
|
tristan@xtalks.com
|
|
|
|
|
|
|
|
|